Data from a meta-analysis study of Mederi Therapeutics Stretta device released this week indicate that treatments with the device reduced heartburn and improved health-related quality of life scores for patients with gastroesophageal reflux disease.
The company’s Stretta catheter system applies low-power radio frequency energy to remodel the lower esophageal sphincter to restore natural barrier function and reduce spontaneous regurgitation caused by transient relaxations of the sphincter.
In the study, researchers analyzed results from 28 studies of the Stretta system, including data from 2,468 unique Stretta patients. Results indicate an average 1.43 improvement to pooled heartburn standardized scores with health-related quality of life scores improving by 14.6.
The rate of erosive esophagitis was lowered by 24%, data indicated, while esophageal acid exposure was reduced by an average of 3.01. Lower esophageal sphincter basal pressure was increased by an average of 1.73, according to the study.
Researchers concluded that due to the improved endpoints in the trial, treatment with the Stretta device “therefore should be considered as a viable alternative in managing GERD.